EUVIMEDEUVIMED entdecken
Open Access

Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC

Jipei Liao, Zejia Yang, Shirin Azarbarzin, Kevin J Cullen, Hancai Dan iD

Head & Neck · 2024-05 · 46 (5) · 1126-1135

DOI: 10.1002/hed.27718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Head & Neck, 2024-03. Verfasst von Jipei Liao und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cisplatin, Head and Neck Neoplasms, Aminopyridines, Morpholines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NCI NIH HHS, National Institute of Dental and Craniofacial Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To find a new strategy to treat cisplatin‐resistant head and neck squamous cell carcinoma (HNSCC), we investigated the effects of EGFR inhibitors on the PI3K/Akt/mTOR pathway and determined the efficacy of EGFR inhibitors in combination with PI3K inhibitors to suppress cell proliferation in cisplatin‐resistant‐HNSCC.

Methods

The cisplatin‐resistant HNSCC cell lines were treated with four FDA approved EGFR inhibitors, which included Gefitinb or Erlotinib alone, or in combination with the pan‐PI3K inhibitor, BKM120. Phosphorylation and total protein levels of cells were assessed by Western blot analysis. Cell proliferation was examined by MTS assay. Apoptosis was analyzed by flow cytometry.

Results

Cisplatin‐resistant HNSCC cells were also resistant to EGFR inhibitors. However, a combination of EGFR inhibitors with PI3K inhibitor BKM120 dramatically improved the efficacy of EGFR inhibitors to inhibit cell proliferation and induce apoptosis. Furthermore, treatment with EGFR inhibitors differentially affected the phosphorylation of Akt and mTOR, which included partial inhibition, no inhibition, and induction. A combination of EGFR inhibitors and BKM120 completely blocked phosphorylation of EGFR, Akt, and S6K (an mTOR target).

Conclusion

Our data provided a rationale for EGFR inhibitors in combination with PI3K inhibitors to treat cisplatin‐resistant HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinHead and Neck NeoplasmsAminopyridinesMorpholinesHumansSquamous Cell Carcinoma of Head and NeckPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionProtein Kinase InhibitorsDrug Resistance, NeoplasmTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsCell ProliferationErbB ReceptorsCell Line, Tumor

Stichwörter der Autor:innen

EGFREGFR inhibitorHNSCCPI3KPI3K inhibitorscisplatin resistancetargeted therapy

Substanzen

NVP-BKM120CisplatinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProtein Kinase InhibitorsTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsErbB ReceptorsEGFR protein, humanAminopyridines

Autor:innen und Institutionen

  • University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Hancai Dan

Förderung

  • NIDCR NIH HHS
  • NCI NIH HHS
  • National Institute of Dental and Craniofacial Research
  • National Cancer Institute

Zitieren

APA

Liao, J., Yang, Z., Azarbarzin, S., Cullen, K. J., & Dan, H. (2024). Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC. Head & Neck, 46(5), 1126-1135. https://doi.org/10.1002/hed.27718

Vancouver

Liao J, Yang Z, Azarbarzin S, Cullen KJ, Dan H. Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC. Head & Neck. 2024;46(5):1126-1135. doi:10.1002/hed.27718

BibTeX
@article{Liao2024,
  author = {Liao, Jipei and Yang, Zejia and Azarbarzin, Shirin and Cullen, Kevin J and Dan, Hancai},
  title = {Differential modulation of PI3K /Akt/ mTOR activity by EGFR inhibitors: A rationale for co‐targeting EGFR and PI3K in cisplatin‐resistant HNSCC},
  journal = {Head & Neck},
  year = {2024},
  volume = {46},
  number = {5},
  pages = {1126--1135},
  doi = {10.1002/hed.27718}
}
Kostenlos starten →